--- title: "U.S. Stock Market Midday Update: Check Cap up 10.34%" type: "News" locale: "en" url: "https://longbridge.com/en/news/257966480.md" description: "Check Cap rose 10.34%; Boston Scientific fell 0.48%, with a transaction volume of USD 688 million; Intuitive Surgical fell 0.05%, with a transaction volume of USD 439 million; Dexcom fell 1.81%, with a transaction volume of USD 427 million; Abbott fell 0.09%, with a market value of USD 233.3 billion" datetime: "2025-09-18T18:32:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/257966480.md) - [en](https://longbridge.com/en/news/257966480.md) - [zh-HK](https://longbridge.com/zh-HK/news/257966480.md) --- # U.S. Stock Market Midday Update: Check Cap up 10.34% **U.S. Stock Market Midday Update** **Stocks with High Trading Volume in the Industry** Boston Scientific, down 0.48%, with a trading volume of $688 million, saw increased trading activity. Based on recent key news: 1. On September 16, Boston Scientific released its latest financial report, showing quarterly revenue below market expectations, leading to a decline in stock price. 2. On September 17, analysts at MarketBeat noted that although Boston Scientific is currently rated as a buy, top analysts believe there are five stocks that are more worthy of investment, further undermining investor confidence. 3. On September 17, Boston Scientific issued a statement on its official website emphasizing its future growth prospects, but the market reacted lukewarmly, and the stock price continued to decline. The medical device industry has recently performed poorly, with weak macroeconomic data. Intuitive Surgical, down 0.05%, with increased trading volume. According to recent key news: 1. On September 18, Intuitive Surgical projected a growth of up to 17% in the number of da Vinci surgeries this year, but gross margins may decline by one percentage point due to tariff impacts. Despite a drop in stock price this year, it still trades at a high price-to-earnings ratio, indicating long-term investment potential. 2. On September 17, investors held an optimistic view of Intuitive Surgical, observing significant capital inflow into the company's stock, reflecting market confidence in its growth potential. 3. On September 16, analysts rated Intuitive Surgical as hold, with a target price of $485, expecting an 8% upside over the next 12 months, but potentially underperforming the market. The industry has significant growth potential, but tariff impacts need to be monitored. Dexcom, down 1.81%, with a trading volume of $427 million, saw increased trading activity. Based on recent key news: 1. On September 15, the U.S. FDA pointed out software design errors in Dexcom's G7 and One+ applications, failing to alert users to sensor failures. This news led to a decline in investor confidence in the company's products, causing the stock price to drop. 2. On September 16, Dexcom announced that CEO Kevin R. Sayer was temporarily stepping down for health reasons, with Jacob S. Leach appointed as interim CEO. This leadership change raised market concerns about the stability of the company's management, further pressuring the stock price. 3. On September 18, reports indicated that at least 60 Dexcom G7 users were hospitalized, with multiple fatalities. The FDA noted that unauthorized material changes by Dexcom affected product accuracy, exacerbating market concerns about the safety of the company's products, leading to a significant drop in stock price. The medical technology industry has recently performed poorly, with low market sentiment. **Stocks with High Market Capitalization in the Industry** Abbott, down 0.09%, with a market capitalization of $233.3 billion. Based on recent key news: 1. On September 18, market analysts believed that Abbott Laboratories' investment value was lower than that of five other stocks, leading to a decline in investor confidence and putting pressure on the stock price. Data source: MarketBeat 2. On September 18, a report from Mirae Asset Sharekhan pointed out that Abbott India's strong financial performance and brand influence help maintain revenue growth, but failed to significantly boost the parent company's stock price. Data source: Mirae Asset Sharekhan. 3. On September 16, the market rating for Abbott Laboratories was "Moderate Buy," but it was not included in the list of stocks recommended by top analysts, affecting market expectations. Data source: MarketBeat. Market analysts are cautious about Abbott ### Related Stocks - [CHEK.US](https://longbridge.com/en/quote/CHEK.US.md) - [MBAI.US](https://longbridge.com/en/quote/MBAI.US.md) ## Related News & Research - [Check-Cap sets post-merger board committee lineup for MBody AI deal](https://longbridge.com/en/news/296398107.md) - [Check-Cap Highlights MBody AI’s Expanded Fortune 500 Robotics Deployment Ahead of Merger](https://longbridge.com/en/news/281235217.md)